Addex Therapeutics Ltd (NASDAQ: ADXN) opened about 70% up this morning after making significant strides in its GABAB-positive allosteric modulator research. The clinical-stage pharmaceutical company has selected candidates for the PAM research that it's undertaking in collaboration with Indivior PLC, as per a press release on Tuesday.